Cited by 588Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular DiseasesParaoxonase enzyme and polymorphisms

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

Open access

The STABILITY Investigators·2014·New England Journal of Medicine

DOI 10.1056/nejmoa1315878

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Elevated lipoprotein-associated phospholipase A2 activity promotes the development of vulnerable atherosclerotic plaques, and elevated plasma levels of this enzyme are associated with an increased risk of coronary events. Darapladib is a selective oral inhibitor of lipoprotein-associated phospholipase A2. METHODS: In a double-blind trial, we randomly assigned 15,828 patients with stable coronary heart disease to receive either once-daily darapladib (at a dose of 160 mg) or placebo. The primary end point was a composite of cardiovascular death, myocardial infarction, or stroke. Secondary end points included the components of the primary end point as well as major coronary events (death from coronary heart disease, myocardial infarction, or urgent coronary revascularization for myocardial ischemia) and total coronary events (death from coronary heart disease, myocardial infarction, hospitalization for unstable angina, or any coronary revascularization). RESULTS: During a median follow-up period of 3.7 years, the primary end point occurred in 769 of 7924 patients (9.7%) in the darapladib group and 819 of 7904 patients (10.4%) in the placebo group (hazard ratio in the darapladib group, 0.94; 95% confidence interval [CI], 0.85 to 1.03; P=0.20). There were also no significant between-group differences in the rates of the individual components of the primary end point or in all-cause mortality. Darapladib, as compared with placebo, reduced the rate of major coronary events (9.3% vs. 10.3%; hazard ratio, 0.90; 95% CI, 0.82 to 1.00; P=0.045) and total coronary events (14.6% vs. 16.1%; hazard ratio, 0.91; 95% CI, 0.84 to 0.98; P=0.02). CONCLUSIONS: In patients with stable coronary heart disease, darapladib did not significantly reduce the risk of the primary composite end point of cardiovascular death, myocardial infarction, or stroke. (Funded by GlaxoSmithKline; STABILITY ClinicalTrials.gov number, NCT00799903.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1315878

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
Bhatt, D. L. (2006) · JAMA · doi:10.1001/jama.295.2.180 · Cited by 1,644
Concept of Vulnerable/Unstable Plaque
Finn, A. V., Nakano, M., Narula, J., Kolodgie, F. D., & Virmani, R. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.108.179739 · Cited by 1,193
Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
Steg, P. G., Greenlaw, N., Tardif, J., Tendera, M., Ford, I., Kääb, S., Abergel, H., Fox, K. M., Ferrari, R., & on behalf of the CLARIFY Registry Investigators (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs289 · Cited by 653
Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies
‡ (2010) · The Lancet · doi:10.1016/s0140-6736(10)60319-4 · Cited by 595
Effects of the Direct Lipoprotein-Associated Phospholipase A 2 Inhibitor Darapladib on Human Coronary Atherosclerotic Plaque
Serruys, P. W. J. C., García‐García, H. M., Buszman, P. E., Erné, P., Verheye, S., Aschermann, M., Duckers, H., Bleie, Ø., Dudek, D., Bøtker, H. E., et al. (2008) · Circulation · doi:10.1161/circulationaha.108.771899 · Cited by 498
Inhibition of lipoprotein-associated phospholipase A2 reduces complex coronary atherosclerotic plaque development
Wilensky, R. L., Shi, Y., Mohler, E. R., Hamamdzic, D., Burgert, M. E., Li, J., Postle, A. D., Fenning, R. S., Bollinger, J. G., Hoffman, B. E., et al. (2008) · Nature Medicine · doi:10.1038/nm.1870 · Cited by 389
Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase, generates two bioactive products during the oxidation of low-density lipoprotein: use of a novel inhibitor
Macphee, C. H., Moores, K., Boyd, H., Dhanak, D., Ife, R. J., Leach, C. A., Leake, D. S., Milliner, K. J., Patterson, R. A., Suckling, K. E., et al. (1999) · Biochemical Journal · doi:10.1042/bj3380479 · Cited by 359
Detection of Chronic Kidney Disease in Patients With or at Increased Risk of Cardiovascular Disease
Brosius, F. C., Hostetter, T. H., Kelepouris, E., Mitsnefes, M. M., Moe, S. M., Moore, M. A., Pennathur, S., Smith, G. L., & Wilson, P. W. F. (2006) · Circulation · doi:10.1161/circulationaha.106.177321 · Cited by 325
Lipoprotein-Associated Phospholipase A 2 Protein Expression in the Natural Progression of Human Coronary Atherosclerosis
Kolodgie, F. D., BURKE, A. P., Skorija, K., Ladich, E. R., Kutys, R., Makuria, A. T., & Virmani, R. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000244681.72738.bc · Cited by 307

Flagged first, then by citations

Show all 22 references

Research works printed but not linked: 1

10.1042/0264-6021:3380479 · DOI

Sorted by citations

Items 401–500 of 588

Dyslipidaemia in perspective
Kastelein, J. J. P. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61332-5 · Cited by 5
The Importance of Age and Statin Therapy in the Interpretation of Lp-PLA2 in ACS Patients, and Relation to CRP
Franeková, J., Kettner, J., Kubíček, Z., & Jabor, A. (2015) · Physiological Research · doi:10.33549/physiolres.932765 · Cited by 5
Report of the European Society of Cardiology Cardiovascular Round Table regulatory workshop update of the evaluation of new agents for the treatment of acute coronary syndrome: Executive summary
Bueno, H., de Graeff, P., Richard‐Lordereau, I., Emmerich, J., Fox, K. A. A., Friedman, C. P., Gaudin, C., Elgazayerly, A., Goldman, S., Hemmrich, M., et al. (2016) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616649859 · Cited by 5
Yes, hyperglycaemia is indeed a modifiable cardiac risk factor: so says Mendel
Bhatt, D. L. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv094 · Cited by 5
Commentary on the OPTIDUAL trial results: how to optimise prolonged dual antiplatelet treatment and independent randomised clinical trials
Wallentin, L. C. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv499 · Cited by 5
Inflammation in HFpEF: Crucial or Ancillary?
Hassoun, R., & Hamdani, N. (2023) · Circulation Heart Failure · doi:10.1161/circheartfailure.123.010887 · Cited by 5
Amino Acid Metabolism and Autophagy in Atherosclerotic Cardiovascular Disease
Wu, Y., Avcilar-Kücükgöze, I., Santovito, D., & Atzler, D. (2024) · Biomolecules · doi:10.3390/biom14121557 · Cited by 5
Natural history and outcomes of medically treated coronary artery disease: insights from reconstructed individual patient data of 29 randomized trials
Mahesh, R., Wong, D., Anand, V. V., Soh, D. K. E., Low, G. Z., Hao, Y., Chen, Y., Chong, B., Hartanto, A. D., Chen, J. N., et al. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02800-7 · Cited by 5
Agreement Between Mega-Trials and Smaller Trials
Kastrati, L., Raeisi‐Dehkordi, H., Llanaj, E., Quezada‐Pinedo, H. G., Khatami, F., Ahanchi, N. S., Llane, A., Meçani, R., Muka, T., & Ioannidis, J. P. A. (2024) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.32296 · Cited by 5
Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomized control trials
Webster, E. R., Perkovic, A., Neuen, B. L., Tuttle, K. R., & Perkovic, V. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf001 · Cited by 6
Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies
Hermans, M. P., Bouénizabila, E., Amoussou-Guénou, D., Ahn, S. A., & Rousseau, M. F. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0226-z · Cited by 4
Lipoprotein‐associated phospholipase A2 predicts lower limb ischemia in hemodialysis subjects
Mauri, A. D., Vidali, M., Chiarinotti, D., Dianzani, U., & Rolla, R. (2019) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13465 · Cited by 4
Current and emerging drugs for the treatment of atherosclerosis: the evidence to date
Rizvi, A. A., Popovic, D. S., Παπάνας, Ν., Stoian, A. P., Almahmeed, W. A., Sahebkar, A., Janež, A., & Rizzo, M. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2094771 · Cited by 4
Lipoprotein associated- phospholipase A2 in STEMI vs. NSTE-ACS patients: a marker of cardiovascular atherosclerotic risk rather than thrombosis
Verdoia, M., Rolla, R., Gioscia, R., Rognoni, A., Luca, G. D., & Novara Atherosclerosis Study Group (NAS) (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02801-1 · Cited by 4
Photochemical acridone-mediated direct arylation of (hetero)arenes with aryl diazonium salts
Li, Z., Chen, L., Rong, D., Yuan, L., & Xie, Y. (2023) · Organic & Biomolecular Chemistry · doi:10.1039/d3ob01389h · Cited by 4
Lipoprotein-associated phospholipase A2 predicts cardiovascular death in patients on maintenance hemodialysis: a 7-year prospective cohort study
Lin, L., Teng, J., Shi, Y., Xie, Q., Shen, B., Xiang, F., Cao, X., Ding, X., Xu, X., & Zhang, Z. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-023-01991-0 · Cited by 4
Using proteomics to identify the mechanisms underlying the benefits of statins on ischemic heart disease
Zhao, J. V., & Zhang, J. (2024) · npj Cardiovascular Health · doi:10.1038/s44325-024-00018-6 · Cited by 4
Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy
Shin, S., Baek, D.-S., Mellors, J. W., Dimitrov, D. S., & Li, W. (2025) · Antibodies · doi:10.3390/antib14010021 · Cited by 4
Phospholipase PAFAH2 Mediates Ferroptosis Surveillance and Lipid Remodeling to Promote Resistance in KEAP1 Mutant Cancers
Ruiz, S. B., Tylawsky, D. E., Shah, J., Saoi, M., Cuevas, B. D., Desai, S. H., Rácz, B., Perea, A., Izawa-Ishiguro, A. R., Cross, J. R., et al. (2025) · ACS Chemical Biology · doi:10.1021/acschembio.5c00273 · Cited by 5
Pharmacological Inhibition of Phosholipase A2: Results from Phase 3 Clinical Trials with Darapladib and Varespladib in Patients with Cardiovascular Disease
Ricci, N. F. C. (2015) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000137 · Cited by 4
Report of the American College of Cardiology (ACC) Scientific Sessions 2014, Washington, DC
Kusunose, K. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-0411 · Cited by 4
Examining anti-inflammatory therapies in the prevention of cardiovascular events: protocol for a systematic review and network meta-analysis of randomised controlled trials
Boczar, K. E., Shin, S., Bezzina, K. A., Geejo, A., Pearson, A., Shahab, S., Fehlmann, C. A., Visintini, S. M., Beanlands, R. S., & Wells, G. A. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-062702 · Cited by 4
Effects of Low-Dose Colchicine on Serum High-Sensitivity C-Reactive Protein Level in Coronary Artery Disease Patients with Type 2 Diabetes Mellitus and Enhanced Inflammatory Response Protocol for a Randomized, Double-Blind, Placebo-Controlled, Phase 2, Dose-Finding Study
Miwa, Y., Mutoh, A., Morimoto, T., Ikehara, Y., Yasu, T., Koba, S., Ako, J., Higashi, Y., Kajikawa, M., Uehara, H., et al. (2022) · Biomedicine Hub · doi:10.1159/000527411 · Cited by 4
Tag-SNPs in Phospholipase-Related Genes Modify the Susceptibility to Nephrosclerosis and its Associated Cardiovascular Risk
González, L. M., Robles, N. R., Mota-Zamorano, S., Arévalo‐Lorido, J. C., Valdivielso, J. M., López-Gómez, J., & Gervasini, G. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.817020 · Cited by 4
The association between uncarboxylated matrix Gla protein and lipoprotein-associated phospholipase A2
Mayer, O., Seidlerová, J., Vaněk, J., Kielbergerová, L., Bruthans, J., Filipovský, J., Wohlfahrt, P., Cífková, R., Trefil, L., Knapen, M. H. J., et al. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.10.003 · Cited by 4
Uppsala Clinical Research Center—development of a platform to promote national and international clinical science
Wallentin, L. C., & Lindahl, B. (2018) · Upsala Journal of Medical Sciences · doi:10.1080/03009734.2018.1540506 · Cited by 4
Review of OxLDL Driven Inflammatory Cell Activation
Ogugofor, M. O., Holmes, D., & Gieseg, S. P. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01357-0 · Cited by 3
Clinical remission in paired phase two and three studies in inflammatory bowel disease: a systematic review with meta-analysis
Tandon, P., Natt, N., Malhi, G., Wong, E. C. L., Matthews, P., Reinisch, W., & Narula, N. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002490 · Cited by 3
Perspectives in the Diagnosis, Clinical Impact, and Management of the Vulnerable Plaque
Alperi, A., Antuña, P., Almendárez, M., Álvarez‐Velasco, R., del Valle-Fernández, R., Pascual, I., Hernández‐Vaquero, D., & y, P. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051539 · Cited by 5
Risk factors of atherosclerotic tissue types in single-vessel and intermediate coronary lesions: a cross-sectional study
Wang, X., Chen, Q., Xu, Y., Wang, Y., Yang, Y., Gu, M., Xu, H., & Zhao, Y. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0456-z · Cited by 3
PLA2G7, caloric restriction and cardiovascular aging
Cao, F., & Lee, R. T. (2022) · The Journal of Cardiovascular Aging · doi:10.20517/jca.2022.08 · Cited by 3
Effect of Statin Treatment on Lipoprotein-Associated Phospholipase A2 Mass and Activity: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials
Sahebkar, A., Reiner, Ž., Almahmeed, W. A., Jamialahmadi, T., & Simental‐Mendía, L. E. (2024) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07634-5 · Cited by 3
Effects of Extended-Release Niacin on Quartile Lp-PLA 2 Levels and Clinical Outcomes in Statin-treated Patients with Established Cardiovascular Disease and Low Baseline Levels of HDL-Cholesterol: Post Hoc Analysis of the AIM HIGH Trial
Lyubarova, R., Albers, J. J., Marcovina, S. M., Yao, Y., McBride, R., Topliceanu, A., Anderson, T. J., Fleg, J. L., Desvigne-Nickens, P. M., Kashyap, M. L., et al. (2019) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248419852955 · Cited by 3
Inflammation in Cardiovascular Disease: From Basic Concepts to Clinical Application
Waters, D. D. (2020) · International Journal of Cardiovascular Sciences · doi:10.36660/ijcs.20200048 · Cited by 3
Investigational new drugs for the treatment of acute coronary syndrome
O'Connor, C. T., Kiernan, T. J., & Yan, B. P. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1094459 · Cited by 3
Lipoprotein-Associated Phospholipase A2 – Pathophysiological Role and Clinical Significance as a Cardiovascular Biomarker
Stankovic, S. D., & Ašanin, M. (2015) · InTech eBooks · doi:10.5772/60608 · Cited by 3
Lipoprotein-associated phospholipase A2, and subsequent cardiovascular events and mortality among patients with coronary heart disease
Benderly, M., Sapir, B., Kalter‐Leibovici, O., & Zimlichman, R. (2016) · Biomarkers · doi:10.3109/1354750x.2016.1171910 · Cited by 3
Atherothrombose
Soehnlein, O. (2017) · Herz · doi:10.1007/s00059-017-4659-x · Cited by 3
Regioselectivity of thiouracil alkylation: Application to optimization of Darapladib synthesis
Guibbal, F., Bénard, S., Patché, J., Meneyrol, V., Couprie, J., Yong-Sang, J., Meilhac, O., & Jestin, E. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.12.052 · Cited by 3
Characterization of PLAC® tests in the quantization of lipoprotein associated phospholipase A2 for assessment of cardiovascular diseases
Zhuo, S., & Yuan, C. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.10.007 · Cited by 3
Comparative Analysis of Risk Stratification Scores in Atrial Fibrillation
Samaras, A., Doundoulakis, I., Antza, C., Zafeiropoulos, S., Farmakis, I. T., & Tzikas, A. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201210113328 · Cited by 3
Lipoprotein-Associated Phospholipase A2 and Aortic Stenosis
Heistad, D. D., & Doshi, H. H. (2015) · JACC. Cardiovascular imaging · doi:10.1016/j.jcmg.2014.11.001 · Cited by 3
Efficacy of new immunomodulatory drugs on major adverse cardiovascular events in patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials
He, D., Li, Y., Jiang, Z., Cao, X., & Luo, R. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05250-1 · Cited by 2
Colchicine in coronary artery and cerebrovascular disease: “Old skin for the new ceremony”
Animati, F. M., Cappannoli, L., Proietti, S., Fracassi, F., Montone, R. A., Ierardi, C., Aurigemma, C., Romagnoli, E., Paraggio, L., Lunardi, M., et al. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i11.110563 · Cited by 3
Different eGFR markers and prediction of cardiovascular risk
Tydén, M., Batra, G., Fellström, B., Held, C., Lindbäck, J., Soveri, I., Svensson, M. K. E., Stewart, R., White, H. D., & Wallentin, L. C. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70050 · Cited by 2
Unraveling the Brain-Heart Axis: More than Inflammation.
Hakimjavadi, R., Kadoya, Y., Liu, P., Rayner, K. J., Beanlands, R. S. B., Tawakol, A., & Boczar, K. (2025) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2025.12.027 · Cited by 4
The person–population paradox in clinical medicine
Horwitz, R. I., Conroy, A. H., Cullen, M. R., & Sim, I. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.01.047 · Cited by 2
Biography as the dark matter of treatment response
Horwitz, R. I., Conroy, A. H., Cullen, M. R., & Sim, I. (2026) · The American Journal of Medicine · doi:10.1016/j.amjmed.2026.01.044 · Cited by 2
Anti-inflammatory therapies to prevent cardiovascular events: systematic review and network meta-analysis of randomised controlled trials
Boczar, K. E., Pearson, A., Hakimjavadi, R., Shin, S., Shahab, S., Geejo, A., Visintini, S. M., Fehlmann, C. A., Bezzina, K. A., Beanlands, R. S., et al. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1717817 · Cited by 2
Effects of anti-inflammatory agents on cardiovascular outcomes: A systematic review and meta-analysis of randomised controlled trials
Perković, A., Webster, E., Ridker, P. M., Tuttle, K., Perkovic, V., & Neuen, B. L. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2026.101642 · Cited by 3
Targeting Inflammation in Atherosclerotic Cardiovascular Disease: Mechanisms and Emerging Therapies
Spindler, M. P., Libby, P., & Ridker, P. M. (2026) · Immunological Reviews · doi:10.1111/imr.70151 · Cited by 3
Twenty-five years of statins: where do we go from here?
Gotto, A. M., & Moon, J. E. (2015) · Clinical Lipidology · doi:10.2217/clp.14.62 · Cited by 2
The possibility of reducing the Lp-PLA2 mass level using simvastatin monotherapy and combination therapy with ezetimibe
Miklishanskaya, S. V., Vlasik, T. N., Kheimets, G. I., & Kukharchuk, V. V. (2015) · Cor et Vasa · doi:10.1016/j.crvasa.2015.03.012 · Cited by 2
Ox-LDL, Lysophospatidy Choline Platelet Activating Factor, IL-6 Expression Level and Foam Cell Number with Darappabdib Treatment in Early Development of Atherosclerosis: In Vivo Study for Type 2 Diabetes Mellitus Model
Heriansyah, T., Siswanto, B. B., Santoso, A., & Sargowo, D. (2016) · Journal of the Hong Kong College of Cardiology · doi:10.55503/2790-6744.1025 · Cited by 2
Phospholipase A2: An emerging biomarker in vascular diseases
Jain, K., Vadak, N., & Bhatt, L. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15313-6.00002-8 · Cited by 2
Safety and Efficacy of Canakinumab for the Prevention and Control of Type 2 Diabetes Mellitus and Its Complications: A Systematic Review
Lanka, N., Acharya, P., Virani, S., Afreen, S., Perthiani, A., Sangster, E., & Franchini, A. P. A. (2024) · Cureus · doi:10.7759/cureus.67065 · Cited by 2
Structural and molecular dynamics insights into the competitive inhibition of the platelet-activating factor receptor by acyl-PAF
Hung, S.-C., Chen, C.-C., Chan, H., Chan, M.-L., Ngui, Y. S., Mei, J.-B., Huang, Y., Chaithra, V. H., Marathe, G. K., & Ke, L. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110831 · Cited by 2
Clinical Outcomes in Trials Evaluating Lipid-Lowering Drugs
Butters, J., Brown, A. D. H., Griffith, L., Kim, H., & Nicholls, S. J. (2017) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-017-0231-6 · Cited by 2
Molecular Imaging of Atherosclerosis
Tawakol, A. A., Narula, J., Narula, J., Narula, J., Narula, J., & Jaffer, F. A. (2012) · Springer eBooks · doi:10.1007/978-1-4614-5551-6_12 · Cited by 3
The year in cardiology 2014: coronary intervention
Iqbal, J., Serruys, P. W. J. C., Albuquerque, F. N., & Wijns, W. C. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu487 · Cited by 2
Tribulations of Recent Cardiology Trials, the Audacity of Hope, and HOPE-3
Waters, D. D., & Chau, K. H.-Y. (2015) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2015.08.020 · Cited by 2
Crystal Structure and Atomic Level Analysis of Plasma PAF-AH
Gonzalez, T. D., & Bahnson, B. J. (2015) · The Enzymes · doi:10.1016/bs.enz.2015.09.001 · Cited by 2
Cholesterol-Lowering Drugs and Therapies in Cardiovascular Disease
Almarzooq, Z., & Singh, P. (2016) · InTech eBooks · doi:10.5772/64762 · Cited by 2
Ensayos clínicos. Una asignatura pendiente
Extremera, B. G., Jiménez-López, P., & Mediavilla-García, J. D. (2017) · Revista Clínica Española · doi:10.1016/j.rce.2017.06.006 · Cited by 2
Clinical trials. A pending subject
Extremera, B. G., Jiménez-López, P., & Mediavilla-García, J. D. (2017) · Revista Clínica Española (English Edition) · doi:10.1016/j.rceng.2017.06.003 · Cited by 2
Association with lipids or detergents is essential for preservation of the active structure of lipoprotein-associated phospholipase A2
Zhuo, S., & Yuan, C. (2019) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2019.104814 · Cited by 2
Comparison of Lp-PLA2 Activity, Lp-PLA2 Mass and Lp-PLA2 mRNA in Acute Coronary Syndrome Patients
Ma, X., Ma, X., Li, Y., Sun, Q., Ding, T., Mu, L., & Yuan, H. (2021) · Journal of Integrative Cardiology Open Access · doi:10.31487/j.jicoa.2021.03.04 · Cited by 2
Darapladib, an inhibitor of Lp-PLA2, sensitizes cancer cells to ferroptosis by remodeling lipid metabolismPreprint
Oh, M., Jang, S. Y., Lee, J.-Y., Kim, J. W., Jung, Y., Seo, J., Han, T., Jang, E., Son, H. Y., Kim, D. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.08.536136 · Cited by 2
Association of loneliness, social isolation, and neuroticism in Alzheimer’s disease risk: a two-step Mendelian randomization studyPreprint
Narayan, V. P., Tanwar, V., Andersen, J. K., & Kapahi, P. (2024) · Research Square · doi:10.21203/rs.3.rs-4351073/v1 · Cited by 2
Proteomic and clinical impact of human knockouts in British South AsiansPreprint
Carrasco-Zanini, J., Pietzner, M., Koprulu, M., Zoodsma, M., Williamson, A., Hunt, K. A., Manolias, A., Walter, K., Martin, H. C., Finer, S., et al. (2025) · medRxiv · doi:10.1101/2025.10.15.25337977 · Cited by 3
Signal terminator or signal initiator? The inscrutable role of lipoprotein-associated PAF-acetylhydrolase (PAF-AH) in inflammation
Swetha, K., Indumathi, M. C., Siddappa, S., & Marathe, G. K. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95696-3.00003-x · Cited by 1
Incretin-Based Therapies, Obesity-Associated Inflammation, and Atherosclerotic Cardiovascular Risk
Kafol, J., Jug, B., & Fras, Z. (2026) · Cells · doi:10.3390/cells15141293 · Cited by 1
Clinical Guidelines on Hyperlipidaemia: Recent Developments, Future Challenges and the Need for an Australian Review
SULLIVAN, D. R., Watts, G. F., Nicholls, S. J., Barter, P. J., Grenfell, R. D., Chow, C. K., Tonkin, A. M., & KEECH, A. C. (2014) · Heart Lung and Circulation · doi:10.1016/j.hlc.2014.12.009 · Cited by 1
The Role of Infections and Microbes in Atherosclerosis
Fong, I. W. (2014) · Springer eBooks · doi:10.1007/978-1-4939-1670-2_9 · Cited by 1
Tooth brushing for a longer and healthier life
van der Wall, E. E. (2016) · Netherlands Heart Journal · doi:10.1007/s12471-016-0802-1 · Cited by 1
From the Masters: Research lessons I’ve learned over a career in vascular medicine
Mohler, E. R. (2017) · Vascular Medicine · doi:10.1177/1358863x17728332 · Cited by 1
In the Heat of the Artery: Inflammation as Trigger and Target of Atherosclerosis
Stachon, P., & Zirlik, A. (2017) · Cardiac and vascular biology · doi:10.1007/978-3-319-66224-4_2 · Cited by 1
The effect of darapladib administration to inflammation marker in early development of atherosclerosis: in vivo study for dyslipidemia model
Heriansyah, T., Aini, F. N., Nafisatuzzamrudah, Saka, P. N. B., Sargowo, D., & Wihastuti, T. A. (2018) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1146/1/012011 · Cited by 1
Lipidsenkende Mittel
Klose, G., & Schwabe, U. (2015) · Springer eBooks · doi:10.1007/978-3-662-47186-9_29 · Cited by 1
Atherosclerosis Imaging
Radfar, A., Abohashem, S., Osborne, M. T., & Tawakol, A. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-09807-9_18 · Cited by 1
Inflammation and Cardiovascular Outcomes
Satish, P., & Agarwala, A. (2024) · Contemporary cardiology · doi:10.1007/978-3-031-54960-1_10 · Cited by 1
La phospholipase A2 associée aux lipoprotéines (Lp-PLA2) : biomarqueur pertinent et cible thérapeutique ?
Bonnefont‐Rousselot, D. (2024) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2024.08.011 · Cited by 1
Atherosclerotic plaque
Singh, P., & Tawakol, A. A. (2015) · Elsevier eBooks · doi:10.1016/b978-1-78242-282-2.00008-1 · Cited by 1
Anti-aging mechanism of calorie restriction in humans
Hasegawa, S., & Nangaku, M. (2022) · Kidney International · doi:10.1016/j.kint.2022.03.016 · Cited by 1
Role of vitamin D in risk factors of patients with type 2 diabetes mellitus
Zhang, Q., Wu, Y., Lu, Y., & Fei, X. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2019.04.037 · Cited by 1
Phospholipase A2 is an Inflammatory Predictor in Cardiovascular Diseases: Is there any Spacious Room to Prove the Causation?
Santoso, A. (2020) · Current Cardiology Reviews · doi:10.2174/18756557otg2podeztcvy · Cited by 1
Development of bioactive bread enriched with a seaweed peptide fraction with potential heart-health effects
Fitzgerald, C. (2014) · UCL Discovery (University College London) · Cited by 1
Prevalence and Prognostic Impact of Periodontal Disease and Conventional Risk Factors in Patients with Stable Coronary Heart Disease
Vedin, O. (2015) · Uppsala University Publications (Uppsala University) · Cited by 1
Another Biomarker for Risk Assessment in Acute Myocardial Infarction?∗
Granger, C. B., & Povsic, T. J. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.06.1200 · Cited by 1
New Risk Factors of Cardiovascular Disease
Acharya, T., & DEEDWANIA, P. C. (2015) · Springer eBooks · doi:10.1007/978-3-319-20415-4_1 · Cited by 1
Will genetic studies deliver the next generation of cardioprotective therapies?
Nicholls, S. J., Ray, K. K., & Grobbee, D. E. (2017) · European Journal of Preventive Cardiology · doi:10.1177/2047487317690960 · Cited by 1
Hemin-driven chromatin remodelling by atherosclerotic risk gene SMARCA4 switches human blood-derived macrophages from leukocyte disposal to erythrocyte disposalPreprint
Cave, L., Lodge, K. M., Chiappo, D., Sinha, S., Chughtai, F., Tsao, A., Haskard, D. O., Mason, J. C., Humphries, S. E., & Boyle, J. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.05.01.538808 · Cited by 1
Outcome Measures for Randomised Clinical Trials and Multicentre Observational Studies of Cardiovascular Diseases Published in Major Clinical Journals: Systematic Review and Evidence MappingPreprint
Bhatty, A., Wilkinson, C., Aktaa, S., Batra, G., Beska, B., Khaing, P. H., Wahab, A., Raveendera, K., Taha, A., Nadarajah, R., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5116096 · Cited by 1
Imaging Plaque Inflammation in Higher-Risk Patients: What Do We Know and What Are We Looking For?
Ishai, A., & Tawakol, A. A. (2015) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-015-0459-0
Incorporating biomarkers into clinical trials in cardiovascular medicine
Ota, S., & Lee, H.-F. (2014) · Current Biomarker Findings · doi:10.2147/cbf.s66258
Biomarker des Lipoproteinstoffwechsels
von Eckardstein, A. (2015) · Cardiovascular Medicine · doi:10.4414/cvm.2015.00297
Learning from anomalies: the case of cholesterol and ischaemic heart disease
Schooling, C. M., & Leung, G. M. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv308
T-cell specificity and regulation in atherosclerosis
Gisterå, A. (2015) · Figshare
Summary of the Clinical Studies Reported in the Annual Scientific Sessions of the American College of Cardiology (Washington D.C., United States, March 29–31, 2014)
(2014) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2014.05.001
Immuno-Inflammatory Basis of Atherosclerotic Coronary Artery Disease
Pothineni, N. V. K., Karathanasis, S. K., & Mehta, J. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00003-6

Authors: The STABILITY Investigators
Affiliations: University of Auckland (NZ)
Corresponding author: The STABILITY Investigators
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2014-05
Volume: 370
Issue: 18
Pages: 1702-1711
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1315878
OpenAlex: W1572528121
Cited by: 579
References: 22
Citations by year: 2026: 23 · 2025: 34 · 2024: 33 · 2023: 27 · 2022: 47 · 2021: 38 · 2020: 34 · 2019: 36 · 2018: 48 · 2017: 63 · 2016: 71 · 2015: 85 · 2014: 37
FWCI: 85.88
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
RECERCAT (Consorci de Serveis Universitaris de Catalunya) (publishedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
The HKU Scholars Hub (University of Hong Kong) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Spiral (Imperial College London) (submittedVersion)
UEA Digital Repository (University of East Anglia) (submittedVersion)
Funders: Uppsala Universitet
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Paraoxonase enzyme and polymorphisms
Keywords: darapladib, lipoprotein-associated phospholipase A2, stable coronary artery disease, cardiovascular events, myocardial infarction, stroke, cardiovascular mortality, major coronary events, all-cause mortality, atherosclerotic plaque vulnerability, lipid-lowering therapy, unstable angina
MeSH terms: Aged, Benzaldehydes, Biphenyl Compounds, Coronary Artery Disease, Coronary Disease, Diethylamines, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Myocardial Infarction, Oximes, Pyrimidinones, Sulfides, Treatment Failure, Stroke, Kaplan-Meier Estimate, Phospholipase A2 Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks